Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study

A. Khojasteh, G. Sartiano, E. Tapazoglou, E. Lester, David R Gandara, S. Bernard, A. Finn

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

To determine a dose-response relationship of ondansetron for the prevention of emesis induced by high-dose cisplatin and to study the efficacy of the extended dosing schedule of ondansetron during 20 hours after cisplatin administration, 36 patients with malignant neoplasms who had not previously received chemotherapy but who were currently receiving cisplatin were treated. These patients received a six-dose regimen of 0.01 mg/kg (low dose) or 0.18 mg/kg (high dose) of ondansetron. Seven (41%) patients in the high-dose group had no emesis and four (24%) patients had one or two episodes. One (5%) patient in the low-dose group had no emesis and four (21%) patients had one or two episodes. The difference in the number of emetic episodes was significant (P<0.02). Fifty percent of the high-dose patients reported no nausea or mild nausea, compared with 11% of the low-dose patients. Clinical adverse events included mild, transient headache and dizziness in the high-dose group and headache and diarrhea in the low-dose group, with no significant laboratory abnormalities. There is a parallel relationship between the ondansetron doses and the antiemetic efficacy. The response rate for the six-dose regimen of 0.18 mg/kg was not superior to that for the previously reported 0.18 mg/kg regimen given in a three-dose schedule in a similar clinical setting.

Original languageEnglish (US)
Pages (from-to)1101-1105
Number of pages5
JournalCancer
Volume66
Issue number6
StatePublished - 1990
Externally publishedYes

Fingerprint

Ondansetron
Cisplatin
Vomiting
Nausea
Headache
Appointments and Schedules
Emetics
Antiemetics
Dizziness
Diarrhea
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Khojasteh, A., Sartiano, G., Tapazoglou, E., Lester, E., Gandara, D. R., Bernard, S., & Finn, A. (1990). Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study. Cancer, 66(6), 1101-1105.

Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study. / Khojasteh, A.; Sartiano, G.; Tapazoglou, E.; Lester, E.; Gandara, David R; Bernard, S.; Finn, A.

In: Cancer, Vol. 66, No. 6, 1990, p. 1101-1105.

Research output: Contribution to journalArticle

Khojasteh, A, Sartiano, G, Tapazoglou, E, Lester, E, Gandara, DR, Bernard, S & Finn, A 1990, 'Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study', Cancer, vol. 66, no. 6, pp. 1101-1105.
Khojasteh A, Sartiano G, Tapazoglou E, Lester E, Gandara DR, Bernard S et al. Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study. Cancer. 1990;66(6):1101-1105.
Khojasteh, A. ; Sartiano, G. ; Tapazoglou, E. ; Lester, E. ; Gandara, David R ; Bernard, S. ; Finn, A. / Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study. In: Cancer. 1990 ; Vol. 66, No. 6. pp. 1101-1105.
@article{86e7f7fa2c2546c3ba39ea14595abbc5,
title = "Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study",
abstract = "To determine a dose-response relationship of ondansetron for the prevention of emesis induced by high-dose cisplatin and to study the efficacy of the extended dosing schedule of ondansetron during 20 hours after cisplatin administration, 36 patients with malignant neoplasms who had not previously received chemotherapy but who were currently receiving cisplatin were treated. These patients received a six-dose regimen of 0.01 mg/kg (low dose) or 0.18 mg/kg (high dose) of ondansetron. Seven (41{\%}) patients in the high-dose group had no emesis and four (24{\%}) patients had one or two episodes. One (5{\%}) patient in the low-dose group had no emesis and four (21{\%}) patients had one or two episodes. The difference in the number of emetic episodes was significant (P<0.02). Fifty percent of the high-dose patients reported no nausea or mild nausea, compared with 11{\%} of the low-dose patients. Clinical adverse events included mild, transient headache and dizziness in the high-dose group and headache and diarrhea in the low-dose group, with no significant laboratory abnormalities. There is a parallel relationship between the ondansetron doses and the antiemetic efficacy. The response rate for the six-dose regimen of 0.18 mg/kg was not superior to that for the previously reported 0.18 mg/kg regimen given in a three-dose schedule in a similar clinical setting.",
author = "A. Khojasteh and G. Sartiano and E. Tapazoglou and E. Lester and Gandara, {David R} and S. Bernard and A. Finn",
year = "1990",
language = "English (US)",
volume = "66",
pages = "1101--1105",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study

AU - Khojasteh, A.

AU - Sartiano, G.

AU - Tapazoglou, E.

AU - Lester, E.

AU - Gandara, David R

AU - Bernard, S.

AU - Finn, A.

PY - 1990

Y1 - 1990

N2 - To determine a dose-response relationship of ondansetron for the prevention of emesis induced by high-dose cisplatin and to study the efficacy of the extended dosing schedule of ondansetron during 20 hours after cisplatin administration, 36 patients with malignant neoplasms who had not previously received chemotherapy but who were currently receiving cisplatin were treated. These patients received a six-dose regimen of 0.01 mg/kg (low dose) or 0.18 mg/kg (high dose) of ondansetron. Seven (41%) patients in the high-dose group had no emesis and four (24%) patients had one or two episodes. One (5%) patient in the low-dose group had no emesis and four (21%) patients had one or two episodes. The difference in the number of emetic episodes was significant (P<0.02). Fifty percent of the high-dose patients reported no nausea or mild nausea, compared with 11% of the low-dose patients. Clinical adverse events included mild, transient headache and dizziness in the high-dose group and headache and diarrhea in the low-dose group, with no significant laboratory abnormalities. There is a parallel relationship between the ondansetron doses and the antiemetic efficacy. The response rate for the six-dose regimen of 0.18 mg/kg was not superior to that for the previously reported 0.18 mg/kg regimen given in a three-dose schedule in a similar clinical setting.

AB - To determine a dose-response relationship of ondansetron for the prevention of emesis induced by high-dose cisplatin and to study the efficacy of the extended dosing schedule of ondansetron during 20 hours after cisplatin administration, 36 patients with malignant neoplasms who had not previously received chemotherapy but who were currently receiving cisplatin were treated. These patients received a six-dose regimen of 0.01 mg/kg (low dose) or 0.18 mg/kg (high dose) of ondansetron. Seven (41%) patients in the high-dose group had no emesis and four (24%) patients had one or two episodes. One (5%) patient in the low-dose group had no emesis and four (21%) patients had one or two episodes. The difference in the number of emetic episodes was significant (P<0.02). Fifty percent of the high-dose patients reported no nausea or mild nausea, compared with 11% of the low-dose patients. Clinical adverse events included mild, transient headache and dizziness in the high-dose group and headache and diarrhea in the low-dose group, with no significant laboratory abnormalities. There is a parallel relationship between the ondansetron doses and the antiemetic efficacy. The response rate for the six-dose regimen of 0.18 mg/kg was not superior to that for the previously reported 0.18 mg/kg regimen given in a three-dose schedule in a similar clinical setting.

UR - http://www.scopus.com/inward/record.url?scp=0025108531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025108531&partnerID=8YFLogxK

M3 - Article

C2 - 2144788

AN - SCOPUS:0025108531

VL - 66

SP - 1101

EP - 1105

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -